Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA Study

Женщины, мужчины и ревматоидный артрит: анализ активности заболевания, характеристик заболевания и лечения в исследовании QUEST-RA
Tuulikki Sokka, Sergio Toloza, Maurizio Cutolo, Hannu Kautiainen, Heidi Mäkinen, Feride Göğüş, Vlado Skakić, Humeira Badsha, Tõnu Peets, Asta Baranauskaitė, Pál Géher, Ilona Újfalussy, Fotini N. Skopouli, Maria Mavrommati, Rieke Alten, Christof Pohl, Jean Sibilia, Andrea Stancati, Fausto Salaffi, Wojciech Romanowski, Danuta Zarowny-Wierzbinska, Dan Henrohn, Barry Bresnihan, Patricia Minnock, Lene Surland Knudsen, Johannes W. G. Jacobs, Jaime Calvo‐Alén, Juris Lazovskis, Geraldo da Rocha Castelar Pinheiro, Д. Е. Каратеев, Daina Andersone, Sylejman Rexhepi, Yusuf Yazıcı, Theodore Pincus, the QUEST-RA Group
2009-01-14

DAS28 remissionDisease activityGender differencesQUEST-RA StudyRheumatoid arthritis
INTRODUCTION: Gender as a predictor of outcomes of rheumatoid arthritis (RA) has evoked considerable interest over the decades. Historically, there is no consensus whether RA is worse in females or males. Recent reports suggest that females are less likely than males to achieve remission. Therefore, we aimed to study possible associations of gender and disease activity, disease characteristics, and treatments of RA in a large multinational cross-sectional cohort of patients with RA called Quantitative Standard Monitoring of Patients with RA (QUEST-RA). METHODS: The cohort includes clinical and questionnaire data from patients who were seen in usual care, including 6,004 patients at 70 sites in 25 countries as of April 2008. Gender differences were analyzed for American College of Rheumatology Core Data Set measures of disease activity, DAS28 (disease activity score using 28 joint counts), fatigue, the presence of rheumatoid factor, nodules and erosions, and the current use of prednisone, methotrexate, and biologic agents. RESULTS: Women had poorer scores than men in all Core Data Set measures. The mean values for females and males were swollen joint count-28 (SJC28) of 4.5 versus 3.8, tender joint count-28 of 6.9 versus 5.4, erythrocyte sedimentation rate of 30 versus 26, Health Assessment Questionnaire of 1.1 versus 0.8, visual analog scales for physician global estimate of 3.0 versus 2.5, pain of 4.3 versus 3.6, patient global status of 4.2 versus 3.7, DAS28 of 4.3 versus 3.8, and fatigue of 4.6 versus 3.7 (P < 0.001). However, effect sizes were small-medium and smallest (0.13) for SJC28. Among patients who had no or minimal disease activity (0 to 1) on SJC28, women had statistically significantly higher mean values compared with men in all other disease activity measures (P < 0.001) and met DAS28 remission less often than men. Rheumatoid factor was equally prevalent among genders. Men had nodules more often than women. Women had erosions more often than men, but the statistical significance was marginal. Similar proportions of females and males were taking different therapies. CONCLUSIONS: In this large multinational cohort, RA disease activity measures appear to be worse in women than in men. However, most of the gender differences in RA disease activity may originate from the measures of disease activity rather than from RA disease activity itself.
1
Gender differences were statistically significant for swollen and tender joint counts, ESR, functional disability, global assessments, pain, DAS28, and fatigue, but effect sizes were small to medium.
2
In the multinational QUEST-RA cohort of 6,004 patients from 25 countries, women had worse scores across all RA disease-activity measures than men.
3
Most apparent gender differences may reflect characteristics of disease-activity measurement rather than intrinsically greater rheumatoid arthritis activity in women.
4
Rheumatoid factor prevalence was similar between genders; men had nodules more often, while women had erosions more often with only marginal statistical significance.
5
Similar proportions of women and men were receiving prednisone, methotrexate, and biologic therapies, suggesting observed activity differences were not explained by treatment utilization.
6
Women had higher mean DAS28 scores than men (4.3 versus 3.8) and achieved DAS28 remission less often, including among patients with no or minimal swollen-joint activity.

Rheumatoid arthritis in adult women and men in the multinational QUEST-RA cohort

Gender differences in RA disease activity, disease characteristics, remission attainment, and use of prednisone, methotrexate, and biologic agents

Publication Details
Publication Date
2009-01-14
Journal
Publisher
ISSN
Access Type
Author Information
Authors
Tuulikki Sokka
Sergio Toloza
Maurizio Cutolo
Hannu Kautiainen
Heidi Mäkinen
Feride Göğüş
Vlado Skakić
Humeira Badsha
Tõnu Peets
Asta Baranauskaitė
Pál Géher
Ilona Újfalussy
Fotini N. Skopouli
Maria Mavrommati
Rieke Alten
Christof Pohl
Jean Sibilia
Andrea Stancati
Fausto Salaffi
Wojciech Romanowski
Danuta Zarowny-Wierzbinska
Dan Henrohn
Barry Bresnihan
Patricia Minnock
Lene Surland Knudsen
Johannes W. G. Jacobs
Jaime Calvo‐Alén
Juris Lazovskis
Geraldo da Rocha Castelar Pinheiro
Д. Е. Каратеев
Daina Andersone
Sylejman Rexhepi
Yusuf Yazıcı
Theodore Pincus
the QUEST-RA Group
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat
Make a presentation
100%